

**FORM 51-102F3  
MATERIAL CHANGE REPORT**

**Item 1. Name and Address of Company**

ME Therapeutics Holdings Inc. (the “Company” or “MET”)  
177 Robson Street  
Vancouver, BC V6B 0N3

**Item 2. Date of Material Change**

October 12, 2023

**Item 3. News Release**

The News Release dated October 11, 2023 was disseminated by Stockwatch and Market News on October 11, 2023.

**Item 4. Summary of Material Change**

The Company announced that its common shares (the “Shares”) are approved for listing on the Canadian Securities Exchange (the “CSE”) effective October 12, 2023 (the “Listing Date”) and will commence trading on the CSE at the market open on the Listing Date under the symbol “METX”.

**Item 5. Full Description of Material Change**

**5.1 Full Description of Material Change**

The Shares will be listed effective October 12, 2023 under the symbol “METX”.

On October 4, 2023, MET was issued a receipt (the “Receipt”) for its final long-form prospectus dated September 29, 2023 (the “Prospectus”), which is available under the Company’s profile on SEDAR+ at [www.sedarplus.ca](http://www.sedarplus.ca).

As of the Listing Date, MET has 23,561,105 Shares outstanding. An aggregate of 18,727,772 Shares are subject to escrow restrictions of which: (i) 14,999,994 Shares (including 12,525,429 Shares which are also subject to escrow pursuant to National Policy 46-201) are subject to restrictions such that 10% of these Shares will be released on the Listing Date, and an additional 30% releases on the dates that are 9, 18 and 27 months after the Listing Date; (ii) 1,000,000 Shares are subject to restrictions such that 25% of these Shares will be released on the Listing Date and the remaining 75% will be released on the date that is 6 months after the Listing Date; and (iii) 15,253,207 Shares (including 12,525,429 Shares which are also subject to the voluntary escrow noted above) are subject to escrow restrictions pursuant to National Policy 46-201 whereby 10% are released on listing and an additional 15% releases on the dates that are 6, 12, 18, 24, 30 and 36 months after the Listing Date.

**5.2 Disclosure for Restructuring Transactions**

Not Applicable.

**Item 6. Reliance on subsection 7.1(2) or (3) of National Instrument 51-102**

Not Applicable.

**Item 7. Omitted Information**

None.

**Item 8. Executive Officer**

Please contact Salim Dhanji, Chief Executive Officer, at 1-236-516-7714.

**Item 9. Date of Report**

October 12, 2023